To the full analysis
Buyback calculator for Mankind Pharma
Mankind Pharma stock: key metrics
MANKIND.NSMankind Pharma had an operating margin of 19.1% and a return on invested capital (ROIC) of 10.9% in fiscal 2026.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2019 | 64.8% | 33.1% | 11.6% |
| 2020 | 92.2% | 25.0% | 17.6% |
| 2021 | 70.6% | 25.9% | 20.4% |
| 2022 | 68.3% | 24.2% | 18.4% |
| 2023 | 66.1% | 18.8% | 14.7% |
| 2024 | 68.3% | 21.8% | 18.6% |
| 2025 | 70.8% | 20.6% | 16.3% |
| 2026 | 43.1% | 19.1% | 13.4% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2019 | 20.5% | 44.8% | 14.1% |
| 2020 | 29.6% | 40.8% | 20.3% |
| 2021 | 26.8% | 42.2% | 19.9% |
| 2022 | 23.3% | 30.8% | 15.7% |
| 2023 | 17.2% | 21.1% | 13.2% |
| 2024 | 20.4% | 28.6% | 16.0% |
| 2025 | 13.9% | 14.7% | 7.2% |
| 2026 | 11.7% | 10.9% | 6.8% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 26 Sep 2025)
- Valuation signal Overvalued since 9 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.